Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 3 Results

Title
Intervention Indication Therapeutic Area Year Actions
Ribociclib with endocrine therapy for HR+/HER2- early breast cancer – adjuvant treatment Endocrine therapy , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer Breast Cancer 2022 View  |  Download
Ribociclib and Fulvestrant and PI3K Inhibitor (Buparlisib or Alpelisib) for HR Positive, HER2 Negative Postmenopausal Breast Cancer – Second or Third Line Alpelisib (BYL719; Piqray) , Fulvestrant (Faslodex) , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer Breast Cancer 2017 View  |  Download
Ribociclib (Kisqali) and fulvestrant for advanced HR positive, HER2‐negative breast cancer in postmenopausal women, first or second line Fulvestrant (Faslodex) , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer Breast Cancer 2017 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications